Art. -Nr.: HY-70013

Abiraterone

(Synonyms: CB-7598)

24 Cited Publications

Kundenbewertung

Based on 24 publication(s) in Google Scholar

Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC₅₀s of 2.5 nM and 15 nM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 154229-19-3
Formel: C₂₄H₃₁NO
Molecular Weight:349.51

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Abiraterone Chemical Structure

CAS. Nr.: 154229-19-3

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (24)
Lösungsmittel & Löslichkeit
- In Vitro
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

CYP17

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	95 μM Compound: Abiraterone	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 29172080]
A549	IC₅₀	35.8 nM Compound: ABT	Inhibition of recombinant human CYP17 expressed in human A549 cell membranes using 17-alpha hydroxyprogesterone as substrate and NADPH as cofactor pretreated for 5 mins followed by substrate and cofactor addition after 60 mins by LC/MS analysis Inhibition of recombinant human CYP17 expressed in human A549 cell membranes using 17-alpha hydroxyprogesterone as substrate and NADPH as cofactor pretreated for 5 mins followed by substrate and cofactor addition after 60 mins by LC/MS analysis	[PMID: 28350999]
B16	IC₅₀	105.61 μM Compound: 5a	Antiproliferative activity against mouse B16 cells measured after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells measured after 48 hrs by MTT assay	[PMID: 38467086]
CWR22R	IC₅₀	9.09 μM Compound: ABI	Antiproliferative activity against human 22Rv1 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human 22Rv1 cells incubated for 72 hrs by SRB assay	[PMID: 38364714]
DU-145	GI₅₀	>10 μM Compound: abiraterone	Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34908406]
ECa-109 cell line	IC₅₀	>32 μM Compound: Abiraterone	Antiproliferative activity against human EC109 cells after 72 hrs by MTT assay Antiproliferative activity against human EC109 cells after 72 hrs by MTT assay	[PMID: 29310026]
GES1	IC₅₀	13.12 μM Compound: Abiraterone	Antiproliferative activity against human GES-1 cells after 72 hrs by MTT assay Antiproliferative activity against human GES-1 cells after 72 hrs by MTT assay	[PMID: 29310026]
HBL-100	GI₅₀	>100 μM Compound: Abiraterone	Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay	[PMID: 29172080]
HEK-293T	IC₅₀	>100 μM Compound: Abiraterone	Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
HeLa	GI₅₀	7.9 μM Compound: Abiraterone	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 29172080]
HeLa	IC₅₀	16.9 μM Compound: Abiraterone	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
HepG2	IC₅₀	59.8 μM Compound: Abiraterone	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
hTERT-BJ	GI₅₀	4.5 μM Compound: Abiraterone	Cytotoxicity against human hTERT-BJ cells assessed as cell growth inhibition after 48 hrs SRB assay Cytotoxicity against human hTERT-BJ cells assessed as cell growth inhibition after 48 hrs SRB assay	[PMID: 29172080]
LNCaP	IC₅₀	2706 nM Compound: Abiraterone	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability measured after 6 days by CellTiter-Glo assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability measured after 6 days by CellTiter-Glo assay	[PMID: 36070471]
LNCaP	IC₅₀	3.29 μM Compound: Abiraterone	Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay	[PMID: 29310026]
LNCaP	IC₅₀	800 nM Compound: Abiraterone	In vitro cytochrome P450 17A1 inhibition was assayed using the rapid acetic acid releasing assay (AARA), utilizing intact P450c17-expressing Escherichia coli or P450c17-LNCaP cells as the enzyme source. In vitro cytochrome P450 17A1 inhibition was assayed using the rapid acetic acid releasing assay (AARA), utilizing intact P450c17-expressing Escherichia coli or P450c17-LNCaP cells as the enzyme source.	[PMID: 12773039]
MCF7	IC₅₀	19.3 μM Compound: Abiraterone	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 27209562]
MCF7	IC₅₀	38.2 μM Compound: Abiraterone	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
MDA-MB-231	IC₅₀	19.2 μM Compound: Abiraterone	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27209562]
MDA-MB-361	IC₅₀	20.4 μM Compound: Abiraterone	Growth inhibition of human MDA-MB-361 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-361 cells after 72 hrs by MTT assay	[PMID: 27209562]
MGC-803	IC₅₀	7.72 μM Compound: Abiraterone	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 29310026]
PC-3	GI₅₀	>10 μM Compound: abiraterone	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34908406]
PC-3	IC₅₀	17.2 μM Compound: AB; Cpd I	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37859725]
PC-3	IC₅₀	5.94 μM Compound: Abiraterone	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29310026]
PC-3	IC₅₀	9.32 μM Compound: Abiraterone	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
PC-3	IC₅₀	91 μM Compound: AB; Cpd I	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 37859725]
RWPE-1	IC₅₀	645 μM Compound: AB; Cpd I	Cytotoxicity against human RWPE-1 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human RWPE-1 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 37859725]
SK-OV-3	IC₅₀	59.5 μM Compound: Abiraterone	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
SW1573	GI₅₀	85 μM Compound: Abiraterone	Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay	[PMID: 29172080]
T47D	GI₅₀	24 μM Compound: Abiraterone	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay Antiproliferative activity against human T47D cells after 48 hrs by SRB assay	[PMID: 29172080]
T47D	IC₅₀	16.9 μM Compound: Abiraterone	Growth inhibition of human T47D cells after 72 hrs by MTT assay Growth inhibition of human T47D cells after 72 hrs by MTT assay	[PMID: 27209562]
T47D	IC₅₀	34.7 μM Compound: Abiraterone	Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36455509]
WiDr	GI₅₀	42 μM Compound: Abiraterone	Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay	[PMID: 29172080]

In Vitro

Significant inhibition of proliferation of the AR-positive prostate cancer cell lines LNCaP and VCaP with doses of Abiraterone ≥5 μM is confirmed^[2]. Abiraterone shows IC₅₀ values of 15 nM and 2.5 nM for the 17,20-lyase and 17α-hydroxylase (CYP17 is a bifunctional enzyme with both 17α-hydroxylase and 17,20-lyase activity). Abiraterone inhibits human 17,20-lyase and 17α-hydroxylase with IC₅₀ of 27 and 30 nM respectively^[3]. Abiraterone inhibits recombinant human 3βHSD1 and 3βHSD2 activity with competitive K_i values of 2.1 and 8.8 μM. 10 μM Abiraterone is sufficient to completely block synthesis of 5α-dione and DHT in both cell lines.Treatment with abi significantly inhibited CRPC progression in the robustly growing subset, effectively putting a ceiling on tumor growth over 4 weeks of treatment (P<0.00001). [³H]-dehydroepiandrosterone (DHEA) depletion and Δ⁴-androstenedione (AD) accumulation are inhibited by Abiraterone in LNCaP, with an IC₅₀<1 μM^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The 0.5 mmol/kg/d Abiraterone treatment dose is previously shown to yield serum concentrations of about 0.5 to 1 μM. Xenograft tumor growth in the control group is widely variable, with some tumors growing slowly and only a subset of tumors exhibiting robust growth^[4]. Following i.v. administration (5 mg/kg) the clearance (Cl) and volume of distribution (V_d) are found to be 31.2 mL/min/kg and 1.97 L/kg, respectively. The AUC_0-∞ (area under the plasma concentration-time curve from time zero to infinity time point) is found to be 2675 ng*h/mL. The terminal half-life (t_1/2) is 0.73 h. Because of high clearance, Abiraterone (ART) is quantifiable only until 2 h following i.v. administration^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 154229-19-3
Appearance Solid
Molecular Weight 349.51
Formel C₂₄H₃₁NO
Color White to off-white
SMILES

C[C@@]12C(C3=CN=CC=C3)=CC[C@]1([C@@]4(CC=C5[C@@](C)([C@]4(CC2)[H])CC[C@@H](C5)O)[H])[H]
Synonyms

CB-7598
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (24)

All Cell Proliferation/Viability AssayRT-PCRWBBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nature

Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. [Abstract]

2012 Jan 22;482(7383):116-9. PMID: 22266943
Cell Res

Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. [Abstract]

2020 Oct;30(10):833-853. PMID: 32499560
Eur Urol

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. [Abstract]

2015 Aug;68(2):228-35. PMID: 24837187

Abiraterone purchased from MedChemExpress. Usage Cited in: Eur Urol. 2015 Aug;68(2):228-35. [Abstract]

Parental and resistant 22RV1 cell lines were exposed to increasing concentrations of Aabiraterone (Abi; 0-1000 μM) for 48 h, and IC50 ranges were determined using WST1 assay and GraphPad Prism for analysis.
Nat Microbiol

An expanded metabolic pathway for androgen production by commensal bacteria. [Abstract]

2025 May;10(5):1084-1098. PMID: 40259019
Cell Death Dis

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein. [Abstract]

2022 Dec 12;13(12):1034. PMID: 36509750

Abiraterone purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Dec 12;13(12):1034. [Abstract]

LNCaP/ABI and 22RV1/ABI cells were treated with DMSO, IDA (0.25 μM), Abiraterone (ABI; 10 μM), and a combination of IDA with ABI for 24 h. XPA mRNA expression was determined by Real-time PCR

Abiraterone purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Dec 12;13(12):1034. [Abstract]

LNCaP/ABI and 22RV1/ABI cells were treated with DMSO, IDA(0.25 μM), ABI(10 μM), and a combination of IDA with Abiraterone (ABI) for 24 h. LC3B expressions were determined by western blot assay.
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Phytomedicine

Erchen Decoction ameliorates the rat model of polycystic ovary syndrome by regulating the steroid biosynthesis pathway. [Abstract]

2025 May 20:143:156852. PMID: 40446578
Anal Chem

Enzymatic and Nonenzymatic Electrochemical Interaction of Abiraterone (Antiprostate Cancer Drug) with Multiwalled Carbon Nanotube Bioelectrodes. [Abstract]

2016 Oct 4;88(19):9347-9350. PMID: 27626107
Prostate Cancer Prostatic Dis

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer. [Abstract]

2024 Sep;27(3):451-456. PMID: 37634036
Cells

Clock-Controlled Mitochondrial Dynamics Correlates with Cyclic Pregnenolone Synthesis. [Abstract]

2020 Oct 19;9(10):2323. PMID: 33086741
Cancers (Basel)

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model. [Abstract]

2023 Aug 15;15(16):4115. PMID: 37627143
Sci Rep

Aptamer-based Field-Effect Biosensor for Tenofovir Detection. [Abstract]

2017 Mar 15;7:44409. PMID: 28294122
J Immunol

Restored Thymic Output after Androgen Blockade Participates in Antitumor Immunity. [Abstract]

2023 Feb 15;210(4):496-503. PMID: 36548468
J Cancer

QiLing Decoction promotes ferroptosis of castration-resistant prostate cancer cells by inhibiting FSP1 in vitro and in vivo. [Abstract]

2023 Jul 16;14(12):2236-2245. PMID: 37576395

Abiraterone purchased from MedChemExpress. Usage Cited in: J Cancer. 2023 Jul 16;14(12):2236-2245. [Abstract]

Cell viability of PC3-AbiR cells induced by Abiraterone (Abi; 20 μM; 48 h) was further decreased in the cells treated with 2% QLD containing serum.

Abiraterone purchased from MedChemExpress. Usage Cited in: J Cancer. 2023 Jul 16;14(12):2236-2245. [Abstract]

Both relative lipid ROS and Fe2+ levels were significantly increased in the Abiraterone (Abi; 20 μM; 48 h) -treated PC3-AbiR cells in the presence of 2%-QLD containing serum.
Bionanoscience

01 February 2017.
Prostate

MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 Expression in Prostate Cancer Cells. [Abstract]

2025 Sep 19. PMID: 40968720
Prostate

Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study. [Abstract]

2017 Dec;77(16):1550-1562. PMID: 28971491
Patent

US20250268958A1.
SSRN

2025 Aug 9.
SSRN

2024 Dec 30.
biorxiv

2024 Jun 9.
Research Square Preprint

2023 Nov 25.
University of Valencia

2020 Jul.
Oncotarget

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. [Abstract]

2016 Sep 13;7(37):59781-59794. PMID: 27486973

Lösungsmittel & Löslichkeit

In Vitro:

DMF : 5 mg/mL (14.31 mM; ultrasonic and warming and heat to 60°C)

Ethanol : 5 mg/mL (14.31 mM; ultrasonic and warming and heat to 60°C)

DMSO : 2.5 mg/mL (7.15 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8611 mL

14.3057 mL

28.6115 mL

5 mM

0.5722 mL

2.8611 mL

5.7223 mL

10 mM

0.2861 mL

1.4306 mL

2.8611 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Protokoll

Cell Assay^[2]

LNCaP and VCaP cells are seeded in 96-well plates and grown in CSS-supplemented phenol red-free or FBS-supplemented media for 7 days. Cells are treated with Abiraterone (5 μM and 10 μM) at 24 and 96 hours after plating and cell viability is determined on day 7 by adding CellTiter Glo and measuring luminescence^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]^[5]

Mice^[4]
Male NOD/SCID mice 6 to 8 weeks of age are surgically orchiectomized and implanted with a 5 mg 90-day sustained release DHEA pellet to mimic CRPC with human adrenal physiology. Two days later, 7×10⁶ LAPC4 cells are injected subcutaneously with Matrigel. Tumor dimensions are measured 2 to 3 times per week, and volume is calculated as length×width×height×0.52. Once tumors reach 300 mm³, mice are randomly assigned to vehicle or Abiraterone treatment groups. Mice in the Abiraterone group are treated with 5 mL/kg intraperitoneal injections of 0.5 mmol/kg/d (0.1 mL 5% benzyl alcohol and 95% safflower oil solution) and control mice with vehicle only, once daily for 5 days per week over a duration of 4 weeks (n=8 mice per treatment). Statistical significance between Abiraterone and vehicle treatment groups is assessed by ANOVA based on a mixed-effect model.
Rats^[5]
Male Sprague-Dawley rats (n=8, 240-260 g) are used. Blood samples (450 µL) are obtained following an i.v. 5 mg/kg dose of ART into polypropylene tubes containing Na₂-EDTA solution as an anticoagulant and at pre-dose, 0.12, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h (a sparse sampling protocol is adopted during blood collection and at each time point blood is collected from four animals). Plasma is harvested by centrifuging the blood using a Biofuge at 1760g for 5 min and stored frozen at -80±10°C until analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (760 KB)
- English - EN (760 KB)
- Français - FR (760 KB)
- Deutsch - DE (760 KB)
- Norwegian - NO (760 KB)
- Español - ES (760 KB)
- Swedish - SV (760 KB)
- Italian - IT (760 KB)
- Portuguese - PT (760 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71. [Content Brief]

[2]. Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82. [Content Brief]

[3]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400. [Content Brief]

[4]. Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9. [Content Brief]

[5]. Kumar SV, et al. Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. Biomed Chromatogr. 2013 Feb;27(2):203-7. [Content Brief]

[6]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / DMF / Ethanol	1 mM	2.8611 mL	14.3057 mL	28.6115 mL	71.5287 mL
DMSO / DMF / Ethanol	5 mM	0.5722 mL	2.8611 mL	5.7223 mL	14.3057 mL
DMF / Ethanol	10 mM	0.2861 mL	1.4306 mL	2.8611 mL	7.1529 mL

Keywords

Abiraterone

24 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Abiraterone

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Abiraterone

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (24)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Abiraterone Related Classifications

Art. -Nr.: HY-70013